VYNE Therapeutics Inc. (VYNE)
| Market Cap | 19.05M -21.7% |
| Revenue (ttm) | 454,000 -25.0% |
| Net Income | -21.46M |
| EPS | -25.07 |
| Shares Out | 667.06K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 93,293 |
| Open | 25.50 |
| Previous Close | 25.45 |
| Day's Range | 23.37 - 28.56 |
| 52-Week Range | 14.03 - 79.75 |
| Beta | 2.01 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About VYNE
As of July 27, 2026, VYNE Therapeutics Inc. was acquired by Yarrow Bioscience, Inc., in a reverse merger transaction. VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company’s lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure... [Read more]
Financial Performance
In 2025, VYNE Therapeutics's revenue was $570,000, an increase of 13.77% compared to the previous year's $501,000. Losses were -$26.48 million, -33.52% less than in 2024.
Financial StatementsNews
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves' Disease and Thyroid Eye Disease
NEW HAVEN, Conn.--(BUSINESS WIRE)--Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimm...
VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience
NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its previously announced special cash dividend (the “Cash Dividend”), ...
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that its Board of Directors has approved a reverse stock split of VYNE's com...
VYNE Therapeutics Slides: Investor presentation
VYNE Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 14, 2026.
VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience
Aggregate cash dividend of an estimated $16.5 million, or an estimated $0.38 per share Aggregate cash dividend of an estimated $16.5 million, or an estimated $0.38 per share
VYNE Therapeutics Quarterly report: Q1 2026
VYNE Therapeutics has published its Q1 2026 quarterly earnings report on May 15, 2026.
VYNE Therapeutics Annual report: Q4 2025
VYNE Therapeutics has published its Q4 2025 annual report on February 27, 2026.
VYNE Therapeutics Transcript: M&A Announcement
VYNE and Yarrow Bioscience will merge, creating a Nasdaq-listed company focused on advancing YB-101, a first-in-class TSHR antibody for Graves' disease and TED. The combined entity is well-funded, with a strong investor syndicate and a cash runway into 2028.
VYNE Therapeutics Press release: M&A Announcement
VYNE Therapeutics issued a press release on December 17, 2025, disclosing material business information to investors.
VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement
NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE”) and Yarrow Bioscience, Inc. (“Yarrow”) today announced that they have entered into a definitive merger agreem...
VYNE Therapeutics Proxy statement: Proxy Filing
VYNE Therapeutics filed a proxy statement on November 12, 2025, providing details for shareholder voting and corporate governance matters.
VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update
Company is progressing its previously initiated strategic review evaluating a range of options to maximize shareholder value, including assessment of internal pipeline opportunities and broader strate...
VYNE Therapeutics Quarterly report: Q3 2025
VYNE Therapeutics has published its Q3 2025 quarterly earnings report on November 6, 2025.
VYNE Therapeutics Earnings release: Q3 2025
VYNE Therapeutics released its Q3 2025 earnings on November 6, 2025, summarizing the period's financial results.
VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update
BRIDGEWATER, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated th...
VYNE Therapeutics Quarterly report: Q2 2025
VYNE Therapeutics has published its Q2 2025 quarterly earnings report on August 14, 2025.
VYNE Therapeutics Earnings release: Q2 2025
VYNE Therapeutics released its Q2 2025 earnings on August 14, 2025, summarizing the period's financial results.
VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo
Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75 Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from Ba...
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202
BRIDGEWATER, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated th...
VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update
Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025 Expected cash runway into 2H 2026 BRIDGEWATER, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VY...
VYNE Therapeutics Quarterly report: Q1 2025
VYNE Therapeutics has published its Q1 2025 quarterly earnings report on May 8, 2025.
VYNE Therapeutics Earnings release: Q1 2025
VYNE Therapeutics released its Q1 2025 earnings on May 8, 2025, summarizing the period's financial results.
VYNE Therapeutics Provides Update on VYN202 Program
BRIDGEWATER, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) verbally informed...
VYNE Therapeutics Transcript: H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
The session highlighted advances in BET inhibitor development for autoimmune and inflammatory diseases, with two lead assets progressing through clinical trials. Repibresib targets vitiligo with a Phase IIb readout expected mid-year, while VYN202 is in Phase Ib for psoriasis, with results anticipated by year-end.
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
BRIDGEWATER, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated t...